Dateline City:
KENILWORTH, N.J.
First Presentation of Overall Survival Data in Patients with Advanced Bladder (Urothelial) Cancer from KEYNOTE-045 Study
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that new data investigating the use of KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, in patients with
previously treated advanced urothelial cancer will be presented at the
Society for Immunotherapy of Cancers (SITC) 31st Annual
Meeting, Nov. 9-13.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more